Benefit–Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit–Risk Models Applied to Vaccines
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1942
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Benefit–Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit–Risk Models Applied to Vaccines ; volume:43 ; number:11 ; day:10 ; month:9 ; year:2020 ; pages:1089-1104 ; date:11.2020
Drug safety ; 43, Heft 11 (10.9.2020), 1089-1104, 11.2020
- Urheber
-
Arlegui, Hugo
Bollaerts, Kaatje
Salvo, Francesco
Bauchau, Vincent
Nachbaur, Gaëlle
Bégaud, Bernard
Praet, Nicolas
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40264-020-00984-7
- URN
-
urn:nbn:de:101:1-2020120511293391849128
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Arlegui, Hugo
- Bollaerts, Kaatje
- Salvo, Francesco
- Bauchau, Vincent
- Nachbaur, Gaëlle
- Bégaud, Bernard
- Praet, Nicolas
- SpringerLink (Online service)
Ähnliche Objekte (12)
Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)
Benefit–Risk Monitoring of Vaccines Using an Interactive Dashboard: A Methodological Proposal from the ADVANCE Project
Risk–benefit and cost–benefit ratio in headache treatment
Constrained Optimization for the Selection of Influenza Vaccines to Maximize the Population Benefit: A Demonstration Project
Predicting Regulatory Product Approvals Using a Proposed Quantitative Version of FDA’s Benefit–Risk Framework to Calculate Net-Benefit Score and Benefit–Risk Ratio
Exploring the Cost-Benefit of Vaccines for Infectious Diseases in Slaughter Pig Production
Joint distribution approaches to simultaneously quantifying benefit and risk
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management
Anaphylaxis to additives in vaccines
Malaria Vaccines: Progress to Date
Correction to: Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth
Veterinary vaccines
Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)
Benefit–Risk Monitoring of Vaccines Using an Interactive Dashboard: A Methodological Proposal from the ADVANCE Project
Risk–benefit and cost–benefit ratio in headache treatment
Constrained Optimization for the Selection of Influenza Vaccines to Maximize the Population Benefit: A Demonstration Project
Predicting Regulatory Product Approvals Using a Proposed Quantitative Version of FDA’s Benefit–Risk Framework to Calculate Net-Benefit Score and Benefit–Risk Ratio
Exploring the Cost-Benefit of Vaccines for Infectious Diseases in Slaughter Pig Production
Joint distribution approaches to simultaneously quantifying benefit and risk
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management
Anaphylaxis to additives in vaccines
Malaria Vaccines: Progress to Date
Correction to: Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth
Veterinary vaccines
Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)
Benefit–Risk Monitoring of Vaccines Using an Interactive Dashboard: A Methodological Proposal from the ADVANCE Project
Risk–benefit and cost–benefit ratio in headache treatment
Constrained Optimization for the Selection of Influenza Vaccines to Maximize the Population Benefit: A Demonstration Project
Predicting Regulatory Product Approvals Using a Proposed Quantitative Version of FDA’s Benefit–Risk Framework to Calculate Net-Benefit Score and Benefit–Risk Ratio
Exploring the Cost-Benefit of Vaccines for Infectious Diseases in Slaughter Pig Production
Joint distribution approaches to simultaneously quantifying benefit and risk
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management
Anaphylaxis to additives in vaccines
Malaria Vaccines: Progress to Date
Correction to: Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth